With the development of new photosensitizers that are activated by light at longer wavelengths, interstitial photodynamic therapy (PDT) is emerging as a feasible alternative for the treatment of larger volumes of tissue. Described here is the application of PDT treatment planning software developed by our group to ensure complete coverage of larger, geometrically complex target volumes such as the prostate. In a phase II clinical trial of TOOKAD vascular targeted photodynamic therapy (VTP) for prostate cancer in patients who failed prior radiotherapy, the software was used to generate patient-specific treatment prescriptions for the number of treatment fibres, their lengths, their positions and the energy each delivered. The core of the software is a finite element solution to the light diffusion equation. Validation against in vivo light measurements indicated that the software could predict the location of an isofluence contour to within approximately ±2 mm. The same software was used 10 Author to whom any correspondence should be addressed. to reconstruct the treatments that were actually delivered, thereby providing an analysis of the threshold light dose required for TOOKAD-VTP of the postirradiated prostate. The threshold light dose for VTP-induced prostate damage, as measured one week post-treatment using contrast-enhanced MRI, was found to be highly heterogeneous, both within and between patients. The minimum light dose received by 90% of the prostate, D 90 , was determined from each patient's dose-volume histogram and compared to six-month sextant biopsy results. No patient with a D 90 less than 23 J cm −2 had complete biopsy response, while 8/13 (62%) of patients with a D 90 greater than 23 J cm −2 had negative biopsies at six months. The doses received by the urethra and the rectal wall were also investigated.
to reconstruct the treatments that were actually delivered, thereby providing an analysis of the threshold light dose required for TOOKAD-VTP of the postirradiated prostate. The threshold light dose for VTP-induced prostate damage, as measured one week post-treatment using contrast-enhanced MRI, was found to be highly heterogeneous, both within and between patients. The minimum light dose received by 90% of the prostate, D 90 , was determined from each patient's dose-volume histogram and compared to six-month sextant biopsy results. No patient with a D 90 less than 23 J cm −2 had complete biopsy response, while 8/13 (62%) of patients with a D 90 greater than 23 J cm −2 had negative biopsies at six months. The doses received by the urethra and the rectal wall were also investigated.
Introduction
Photodynamic therapy (PDT) combines a light sensitive compound (photosensitizer) with light to generate reactive oxygen species, which, in sufficient quantities, lead to tissue destruction (Dougherty et al 1998) . Early development of PDT focused on treating surface lesions because light penetration at the activation wavelengths of early photosensitizers was very low. The development of photoactive compounds that absorb light at longer wavelengths, with greater penetration in tissue, has led to the development of treatments for larger, deep-seated tumours. The development of prostate PDT in particular has accelerated rapidly in recent years (Wilson and Patterson 2008) . Relatively easy access to the gland by optical fibres and the ability to harness existing brachytherapy technology has led to several clinical investigations of PDT as a treatment for prostate cancer (Windahl et al 1990 , Nathan et al 2002 , Zaak et al 2003 , Moore et al 2006 , Patel et al 2008 , Trachtenberg et al 2008 . These studies have demonstrated the feasibility of interstitial PDT as a treatment option for prostate cancer.
The PDT threshold model assumes that the target tissue must receive a threshold dose to be treated (Patterson et al 1990 , Dougherty et al 1998 . The goal of PDT treatment planning is then to provide a prescription for the treatment conditions that will satisfy the minimum dose requirement for the target tissue while minimizing the dose received by adjacent normal structures, thus optimizing the treatment for efficacy and safety. Since prostate cancer is generally multi-focal and distributed throughout the gland (Blennerhassett and Vickery 1966 , Byar et al 1972 , McNeal et al 1988 , the target volume in most prostate protocols at the time the trial was initiated was the entire prostate gland. The organs that must be spared are the rectum, urethra, bladder, urinary sphincters and neurovascular bundles.
Typically, prostate PDT involves systemic injection of a photosensitizer and local light delivery by transperineal placement of optical fibres under trans-rectal ultrasound guidance. We believe that individualized treatment planning is required because the number of fibres, the characteristics of the light sources and their positions will vary with the volume and shape of each prostate. Inter-patient anatomical variation, combined with the prostate's proximity to critical structures, has led to the standard use of treatment planning for both external beam radiotherapy (EBRT) of the prostate and prostate brachytherapy (Rivard et al 2004) .
Planning for PDT is, however, more complex than for radiotherapy. Unlike radiotherapy, the intrinsic properties that govern light distribution in tissue vary markedly from patient to patient (Lee et al 1999 , Weersink et al 2005 , Svensson et al 2007 and can also be heterogeneous within each individual , Svensson et al 2007 . Furthermore, successful PDT requires sufficient photosensitizer concentration and oxygen. While there is some evidence that the level of tissue oxygenation can be considered homogenous and constant (Yu et al 2006 , Svensson et al 2007 , both inter-and intra-patient variations in photosensitizer concentration have been noted in the prostate even for the same delivered drug dose (Weersink et al 2005 .
The complex interaction between light, photosensitizer and oxygen and the heterogeneity in light and drug distribution in the prostate highlight the importance of treatment planning for prostate PDT. Two other groups currently engaged in clinical trials of prostate PDT have also developed treatment planning. In a phase I study of prostate PDT using motexafin lutetium, Du et al (2006) mention the creation of treatment plans. These plans appear to be based solely on the requirement to achieve a pre-determined 1 cm spacing between the cylindrical diffusers that deliver the activation light but the same group has also presented optimization algorithms that are capable of specifying the number of diffusers required to treat the prostate as well as their lengths, positions and powers (Altschuler et al 2005 , Li et al 2008 . Their light dosimetry is based on an analytical solution to the diffusion equation and the optimization is based on the Cimmino feasibility algorithm. The same approach to PDT dosimetry optimization is taken by Johansson et al (2007) at Lund University. The light distribution calculated by their system is also based on an analytical solution to the diffusion equation but heterogeneities in the optical properties are accommodated by assigning different optical attenuation properties to each bare fibre light source. Both groups have also developed numerical solutions to the diffusion equation based on the finite element method, but these have only been used in the development of their optimization routines and have not been reported for prospective treatment planning. At the time of writing, the Lund group had just begun a phase I trial of δ-aminolaevulinic acid-mediated prostate PDT so data on the performance of their system in a clinical setting were not available.
Several other groups have developed models for interstitial light delivery. The models are based on semi-empirical relations (Fenning et al 1994) , various analytical solutions to the diffusion equation (Bolin et al 1987 , Arnfield et al 1989 , Grossweiner, 1991 , Dickey et al 2004 , Jankun et al 2005 , Rendon et al 2008 or Monte Carlo simulations of photon transport (Zaak et al 2003) . Semi-empirical relations are usually applicable only to specific cases. The diffusion approximation to modelling light transport works well for biological tissues at typical far-red or near-infrared PDT treatment wavelengths, where light scattering dominates over absorption, but analytical solutions are limited to homogenous optical properties. Monte Carlo simulations are capable of predicting light transport in any media but are often computationally intense and therefore of limited clinical utility (Barajas et al 1997) . Numerical solutions of the diffusion equation, as used here, allow for the modelling of light transport in systems with parameters that vary both in space and over the course of the treatment in time frames that are feasible for clinical application.
In the following sections, we describe the implementation of a treatment planning software package developed at the University Health Network, Toronto, Canada, and applied to a phase II clinical trial of TOOKAD-mediated photodynamic therapy of persistent or recurrent prostatic carcinoma following external-beam radiotherapy (EBRT) (Trachtenberg et al 2008) . It is, to the best of our knowledge, the first description of the clinical application of patientspecific prospective PDT treatment planning based on predicted light distributions in the prostate and surrounding tissues. Section 2 describes the treatment planning software and how it was used in the clinical trial. Section 3 describes how the same software was used to reconstruct the treatments that were delivered and how these reconstructions were used to evaluate the accuracy of the light fluence predictions and to evaluate the threshold light dose using analysis techniques adapted from radiotherapy. A discussion of the results follows in section 4.
Pre-treatment planning

TOOKAD-VTP of the prostate
PDT treatment planning was implemented in a multi-centre phase II clinical trial of the photosensitizer TOOKAD (palladium-bacteriopheophorbide, Padoporfin, WST09, STEBA Biotech, Netherlands), for treatment of recurrent or persistent prostatic carcinoma in patients who had prior EBRT. TOOKAD is a vascular-targeted photosensitizer whose clearance rate, compared with previous photosensitizers, is very fast (Huang et al 2005 . The clinical and technical aspects of the treatment, also referred to as vascular targeted photodynamic therapy (VTP), are described briefly here and in detail elsewhere (Trachtenberg et al 2008 , Weersink et al 2005 .
Twenty-eight patients were included in the trial, with twenty four in the 'per-protocol' cohort. Patients were given general anaesthetic and placed in the lithotomy position. Using a modified brachytherapy stabilizing system with trans-rectal ultrasound guidance, transparent hollow closed-end catheters were inserted across the perineum into the prostate. Treatment fibres with cylindrically diffusing tips were inserted into the catheters to deliver 763 nm light, to match the photosensitizer absorption spectrum. Detector fibres with isotropic tips were inserted into separate catheters within the prostate, the urethra and the rectum. The prostate was physically separated from the rectum by injecting sterile saline in a technique called hydrodissection (Sherar et al 2001) . Once all fibres were in place and the light intensities in the prostate, the urethra and the rectum were checked, infusion of the photosensitizer began. The drug dose was fixed at 2 mg kg −1 and infused at a constant rate over 20 min. Illumination from a diode laser at 763 nm began 6 min after the drug infusion was started in order to centre the illumination about the peak of the photosensitizer's average plasma concentration curve.
MRI scans of the patient's pelvic area were performed 1-4 weeks prior to treatment and one week, one month and six months following treatment. Both the pre-and post-treatment imaging studies included a transverse T2-weighted series and a transverse T1-weighted series with gadolinium contrast enhancement. The patient follow-up also included sextant biopsy six months post-treatment.
Treatment planning was performed, as follows, in order to determine the optimal position, diffuser length and power of each light delivery fibre.
Modelling light distribution in tissue
The core of the PDT treatment planning software is the calculation of the light intensity (fluence rate) distribution in tissue generated by an array of cylindrically diffusing optical fibres. The light distribution is modelled using the diffusion equation:
where φ is the local fluence rate (W cm
, μ a and μ s are, respectively, the absorption and reduced scattering coefficients of the tissue (cm −1 ), and ν is the speed of light in tissue (cm s −1 ). This equation has proven to be accurate when μ s μ a , which is the case in prostate tissue at 763 nm (Weersink et al 2005) .
Due to the potential requirement of simulating light transport in an optically inhomogeneous environment, a numerical approach to solving the diffusion equation was developed using the finite element method (FEM). The volume of interest was discretized into a mesh of 4-noded tetrahedral elements. The simulation time was also broken down into time steps of length t. For each element, e, a system of equations was built at each time step using the following expression:
where
and
In equations (2b) and (2c), e and e represent the volume and boundary, respectively, of element e, the subscript t− t refers to the previous time step and (N k ), k = 1 . . . 4, are the linear shape functions of the 4-noded tetrahedral element, which determine the behaviour of the fluence rate inside the element. The diffusing fibres are modelled as cylindrical voids in the finite element mesh and the light emitted by the fibres is treated as a boundary condition on the surface of the voids. The integral over the element boundary in equation (2c) arises from that boundary condition. It is assumed that the diffusers emit uniformly and isotropically and that the intensity at the diffuser surface is proportional to the power, P (W), divided by the surface area, A (cm 2 ), i.e.
where n is the vector normal to the surface of the diffuser. The boundary integral in equation (2c) is evaluated only for element sides that border on a cylindrical diffuser. The fluence rate at the outer boundary of the computational domain is set to zero. Since the light emitted by the diffusers is modelled as a boundary condition, S = 0. The element matrices are assembled into global matrices, taking into account the element connectivity, and the global system of equations is solved at each time step to obtain the nodal fluence rates (φ j ). The total light energy density, or fluence (J cm −2 ), is determined at each time step by multiplying the fluence rate (φ) by the duration of the time step ( t). This light distribution calculation has been validated against analytical solutions to the diffusion equation and Monte Carlo simulations .
Mesh generation was performed by Geompack (ZCS Inc., Canada). The urethra and the cylindrical diffuser array are represented in the mesh but the prostate and the rectum are not, i.e. the locations of the mesh nodes are not forced to conform to the contours of the prostate or the rectum. Mesh refinement operations were typically performed on all elements inside the prostate and the rectum to increase the mesh density (and, hence, the accuracy of the calculation) in those structures. The solution to the diffusion equation was coded in C++ using the Diffpack class libraries (inuTech GmbH, Germany).
The effectiveness of a PDT treatment depends not only on the light dose but also on the amount of photosensitizer and oxygen in the tissue. The software assumes an unlimited amount of oxygen and calculates a PDT dose, D PDT , (Mang 2008 ) from the following expression:
where ε is the photosensitizer's mass extinction coefficient, C is the local tissue photosensitizer concentration and F is the singlet oxygen quantum yield. The PDT dose model expressed in equation (4) was developed for cellular-targeting photosensitizers but there is evidence that it can be applied also to vascular-targeted drugs such as TOOKAD (Jarvi 2005) . The extinction coefficient of TOOKAD in solution has been reported for dimethyl sulfoxide and in chloroform Hence, discussion of the threshold dose for this treatment will be limited to light dose values (J cm −2 ) but because the dose calculations are based on the finite element method, the spatial distribution of the photosensitizer can be easily incorporated when it is known and then a threshold PDT dose can be determined.
The treatment planning software and the life cycle of a treatment plan
The PDT treatment planning software includes not only the PDT simulation described in the previous section but also all the tools required to generate patient-specific treatment plans for minimally invasive therapies. These tools are described briefly in this section in the context of the treatment planning process for the TOOKAD-VTP trial, but are generic and could be used for any photosensitizer and target organ.
Treatment plans were based on pre-treatment transverse T2-weighted MRI images. Image scaling and inter-image distances were read directly from the DICOM headers. The image set defined a 3D space in which the other structures were defined.
The outline of the prostate was traced on all images where it was visible (see figure 1 ). The contour of the rectum was traced on all images where the prostate was visible. The centre of the urethra was identified on all images where it was visible and these points were connected by a segmented tube 0.5 cm in diameter. Identification of the target structures was performed or supervised by an experienced radiologist (MAH). Hydrodissection (see section 2.1) was not modelled since the distance between the prostate and the rectum varied from patient to patient and could not be known a priori.
Typically between four and six virtual cylindrical diffusers were placed inside the prostate. The number depended on the prostate volume (maximum of six per trial protocol). The diffuser length (in increments of 0.5 cm), power (W cm −1 ) and energy (J cm −1 ) were specified for each treatment fibre. The illumination time was fixed at 30 min. The power was limited to a maximum of 200 mW cm −1 to avoid tissue thermal effects so that the maximum delivered energy per fibre was 360 J cm −1 . Prostate optical property measurements were made in a previous trial and throughout this trial by fitting a diffusion-based model to the in vivo fluence rate measurements (Weersink et al 2005) . In 67% of the patients, the R 2 value of the fit was >80% (Weersink 2008) , indicating that the prostate optical properties at 763 nm did not vary significantly within the prostate. It was, therefore, assumed that the optical properties within the prostate were homogeneous. The effective optical attenuation coefficient for the population was 2.0 ± 0.6 cm −1 , indicating that there was some inter-patient variability. Optical properties for tissues other than the prostate were not available but it was assumed that some differences in the optical properties outside the prostate would not significantly affect the light distribution calculations inside the prostate and so prostate optical properties were applied throughout the computational domain. The absorption and reduced scattering coefficients applied in each treatment plan were a running average of measurements made in previous patients.
A time step of t = 10 s was used in the dose calculation. Since all parameters were time-invariant, equation (2a) was solved in the first two time steps to allow convergence of the fluence rate solution and in the remaining time steps only the total fluence ( ) and PDT dose were updated.
To evaluate the treatment prescription, the light dose distribution was superimposed onto the MRI images of the target volume as a set of iso-dose contours. One contour represented the threshold dose for VTP-induced damage in the prostate (see section 3.3 for details) while another represented the threshold dose for severe urethral damage (see section 3.6). It was assumed in all the treatment plans that the rectum has the same sensitivity as the prostate to TOOKAD-VTP.
For an effective treatment, it was considered that the threshold contour for prostate tissue should encompass the entire prostate plus a small margin. In order to minimize the risk for adverse events, it was prescribed that the same threshold contour should avoid the rectum and that the iso-dose contour for urethral damage should avoid the urethra. Further evaluation of the dose distribution was performed by calculating the dose-volume histograms (DVH) for the critical structures. The prostate DVH provided the prostate volume that received a planned light dose above the threshold for prostate tissue. The urethral and rectal histograms provided the volumes of over-dosed urethra and rectal tissue. If the light distribution failed to meet the requirements for efficacy and safety, the treatment parameters were iteratively adjusted until the requirements were met. The adjustments were performed manually; the software did not have inverse planning capabilities.
Typically, several treatment options were generated. In some cases, the same dose coverage could be achieved using different strategies but typically, the different treatment options represented different balances between safety and efficacy. For example, figure 2 illustrates two treatment options for the same patient. The more aggressive option delivers the threshold dose to 79.9% of the prostate but over-doses 1.0 cm 3 of the rectum. By shortening the diffusers and reducing their energy output, the rectal over-dose is eliminated but only 63.4% of the prostate receives the threshold dose. Approval of a treatment option was done by the trial's lead physician (JT).
Although no formal dose escalation scheme was imposed, the delivered light dose increased over the course of the trial. Since this was our first experience using multiple light sources to treat the entire prostate, caution was exercised in developing prescriptions for the initial patients. Thus, in the first six patients, the treatment planning simulations predicted 78%-94% coverage of the prostate. In all but one of the remaining per-protocol patients, the dose coverage was >90%. The treatment plans for most patients (20/24) indicated some degree of excess dose delivered to the rectum (maximum volume: 1.1 cm 3 , median: 0.3 cm 3 ). Since there were no data available from the pre-clinical or prior clinical experience on the sensitivity of the urethra to TOOKAD-VTP, the threshold dose for urethral damage was initially set equal to that for prostate tissue. As a result, some urethral tissue over-dosing was predicted (maximum 1.4 cm 3 ) in earlier patients. It will be shown in section 3.6 that, over the course of the trial, the clinical outcomes indicated that the threshold dose for urethral damage was very high and, in later patients, the urethral threshold dose increased to a point where there was consistently no predicted over-dosing. When calculating the dose received by the rectum and the urethra, a margin of 2 mm was added to both structures and the over-dosed tissue volumes reported here include tissue within these margins. A report document for the approved treatment option was generated and brought into the operating room to guide the placement of fibres and define the laser settings. The treatment planning software could not co-register pre-treatment MRI with trans-rectal ultrasound and, therefore, fibre positions were defined by their distances to identifiable landmarks (the urethra and the lateral and posterior prostate capsule).
The time required to generate a finite element mesh and run a light dose calculation typically varied from 10 to 20 min for a 1 GHz processor with 654 MB RAM. Increasing the number of fibres and the fibre lengths increased the number of elements in the mesh and led to longer computation times. Depending on the treatment parameters being simulated and the number of treatment options generated, the total time to create a treatment plan was 2-5 h.
Treatment reconstruction and analysis
The delivered treatment usually deviated to some extent from the planned treatment. In many cases, the tough, fibrotic nature of the previously irradiated prostate tissue made it difficult to place the fibre insertion catheters in their planned positions. In some cases, differences in the appearance of the prostate between MRI and ultrasound led to the selection of different diffuser lengths. In most cases, the optical properties measured for a patient were different from the average optical properties used in the patient's treatment plan. Treatment reconstructions were performed using the treatment planning software to simulate the actual treatment conditions and so provide a more realistic context for the analysis of the treatment results.
Creation of a treatment reconstruction
The creation of a post-treatment reconstruction was very similar to that of a pre-treatment plan (section 2.3). Reconstructions were performed for all but one of the patients, who was not part of the per-protocol population, and for whom the contrast in the intra-operative ultrasound images was poor and the positions of the delivery fibres could not be reconstructed.
The prostate, the rectum and the urethra were defined on the T2-weighted image series acquired one week post-treatment. The post-treatment contrast-enhanced T1-weighted MRI series was loaded into the software and registered with the T2 series. Based on pre-clinical experience (Huang et al 2006) , areas of low enhancement (low perfusion) inside the prostate and rectal wall were identified as areas of VTP-induced damage caused by de-vascularization. The non-enhancing areas were traced and the damage volumes were calculated by adding the traced areas from each image and multiplying by the image slice thickness. Further information on the appearance of prostate tissue following VTP is given by Haider et al (2007a) . The estimated error of the damage volumes was calculated for each patient by assuming a ±0.8 mm error in the position of a point on a traced contour, equivalent to approximately ±1 pixel in the underlying MR image. The volume error is larger for smaller volumes, but for a nominal volume of 10 cm 3 the maximum possible error is approximately ±20%. The distances from each delivery fibre to the other delivery fibres and to the urethra and prostate capsule were measured on transverse ultrasound images acquired during the treatment. The depth of insertion of each fibre was determined from transverse and sagittal ultrasound images. The diffuser lengths and powers were recorded during the treatment. These data were used to re-create the actual configuration of diffusers used in the patient (see figure 3) . The positions of the intra-prostatic dosimetry probes were measured in the same fashion and added to the treatment reconstruction to extract light intensity (fluence rate, W cm −2 ) predictions at those specific locations.
The optical properties used in the reconstruction were those measured for the individual patient. In the few patients where it was not possible to calculate optical properties, the population-average optical properties were used.
Validation of the light dose calculation
The light distribution calculation was validated by comparing fluence rate measurements made at the beginning of each treatment prior to TOOKAD infusion with fluence rate data extracted from the treatment reconstructions at locations corresponding to the dosimetry probe positions. The comparison between measured and reconstructed data is given in figure 4 .
There are several reasons for the differences between measured and predicted fluence rates. Transfer of the source and detector fibre positions from intra-prostatic ultrasound to the MRI-based reconstructions was done without automation and was complicated by differences Of the 28 patients included in the trial, 4 were not included in figure 4 because of poor visualization of the dosimetry probes in the ultrasound images (n = 2) or extremely poor agreement between measured and predicted fluence rates, suggesting that one or more of the dosimetry fibres were damaged or placed in a region of extremely high light attenuation (n = 2).
Threshold light dose based on dose received at the damage border
The light dose at the border between non-perfused and normal tissue represents the local threshold dose for tissue damage. The reconstructed light dose distribution was sampled at 1 mm intervals along the intra-prostatic borders of the non-perfused tissue ( figure 5(a) ) to generate a threshold dose histogram for each patient ( figure 5(b) ). The sensitivity of the prostate tissue to TOOKAD-VTP was found to be heterogeneous within each patient. A single representative value, referred to as D T,db (Threshold Dose, damage border), was extracted from each patient's threshold dose histogram. A conservative value was selected because of the emphasis on patient safety, so that D T,db was set equal to the 10th percentile of the histogram, as illustrated in figure 5(b) . Throughout the treatment phase of the trial, the threshold dose for prostate tissue applied in a patient's treatment plan was the median D T,db of all previous patients. Since these values were taken from the low end of each patient's threshold dose histogram, D T,db represents an estimate of the minimum light dose required for tissue response. Thus, as illustrated in figure 5(c), the location of the D T,db iso-dose contour predicted the maximum extent of prostatic damage. However, because the selected D T,db values were conservative the volume inside the contour also included unaffected tissue with a higher threshold dose. Thus the total volume inside the threshold contour was always greater than the actual damage volume.
The D T,db values ranged from 10.2 to 199.6 J cm −2 in the per-protocol population (median: 49.6 J cm −2 , standard deviation: 42.7 J cm −2 ).
Threshold light dose based on dose response curves
Following the treatment phase of the trial, histograms of the light distribution in both the perfused and non-perfused prostate tissue were built for each patient (see examples in figures 6(a)-(b)) by sampling the fluence distribution in 1 mm × 1 mm × 1 mm voxels throughout the prostate. The light dose values at the voxel centres were added to the perfused or non-perfused tissue histogram, based on whether the voxel was inside or outside the damage contours. Histogram bins with a voxel count less than 0.1% of the total number of voxels were removed to reduce sampling errors. The histograms were then converted to dose response curves to show the relative proportion of perfused and non-perfused tissue as a function of the light dose received locally by the tissue (see figures 6(c)-(d)). In some patients, the proportion of damaged tissue rose as the light dose received by the tissue increased and >90% response was achieved at the higher local light doses ( figure 6(c) ). In other patients, despite very high light doses, the proportion of non-perfused tissue remained low ( figure 6(d) ).
The threshold light dose (D T,50% ) defined using this analysis is the value above which the proportion of non-perfused tissue remains consistently above 50%. A D T,50% value could be defined for 13/24 patients in the per-protocol population. The D T,50% values ranged from 18.0 to 437.2 J cm −2 (median: 124.2 J cm −2 , standard deviation: 132.9 J cm −2 ). In the remaining 11 patients, the proportion of non-perfused tissue did not rise consistently above 50%.
The two response types exemplified by figures 6(c)-(d) support the hypothesis that there are at least two populations of patients, or perhaps two tissue types: one that is intrinsically 'resistant' to damage induced by TOOKAD-VTP at the delivered drug dose (2 mg kg −1 ), the other amenable to the treatment. In those patients who show a dose response similar to that in figure 6(c), it is reasonable to conclude that, given a sufficient light dose distributed throughout the prostate, a large volume of non-perfused tissue can be achieved. From figure 7, we see that as the proportion of the prostate receiving a light dose greater than D T,50% increases, so does the amount of prostate tissue damage observed one week post-treatment. In patients with 'poor' dose response, increasing the delivered light dose would not appear to significantly increase the total damage volume.
Minimum light dose for complete biopsy response
Treatment response was also measured six months post-treatment with sextant biopsies, which was the standard for prostate biopsies at the time the trial was conducted. Since the location of the biopsies could not be accurately included in the treatment reconstructions, biopsy response was compared to the overall light dose distribution within the prostate rather than the light dose received at the biopsy location. For each patient, a dose-volume histogram (DVH) of the prostate plotted the light dose calculated from the treatment reconstructions versus the percent organ volume that receives at least that dose (see example in figure 8) .
The minimum light dose received by 90% of the prostate, D 90 , was extracted from the DVH of each patient. Figure 9 plots the D 90 values against biopsy response, expressed as the proportion of negative biopsies at six months post-treatment (e.g. if 6/6 biopsy cores were negative, then the biopsy response was 100%). The D 90 value is a measure of how much light was received and not a measure of the intrinsic sensitivity of each patient to TOOKAD-VTP. For example, one patient received a D 90 of 33.5 J cm −2 and had a complete biopsy response. It is not known, however, whether the same patient would have had a complete response if the D 90 value was lower. By raising the minimum D 90 , the chances for a complete response increase. For example, from figure 9, we see that a D 90 of 40 J cm −2 is sufficient for at least five of the eight patients with complete response. Raising the minimum light dose, however, also increases the risk for over-dosing critical structures.
Threshold light dose for urethral damage
Partial de-vascularization of the urethral wall was noted at seven days post-treatment in 14 of the 24 per-protocol patients but no long-term complications were reported so the urethra appears to be relatively insensitive to VTP-induced damage. Consequently, a threshold light dose for urethral damage was not calculated. Instead, the maximum light dose received by the urethra, which was derived from the reconstructed light dose distribution, was adopted as a conservative estimate of the threshold for urethral complications. The value was periodically updated throughout the trial as the delivered light doses increased.
In those patients with urethra wall involvement, the maximum received light dose varied from 46.7 to 1166.7 J cm −2 (median: 466.3, standard deviation: 354.4 J cm −2 ), while in patients with no evidence of urethral damage, the maximum dose varied from 123.1 to 1658.0 J cm −2 (median: 511.8, standard deviation: 468.9 J cm −2 ). The difference was not statistically significant, although the variance is large so it is not possible to draw definitive conclusions.
Threshold light dose for rectal damage
Nine of the per-protocol patients had MRI-observable rectal hypo-perfusion that in most cases did not extend through the full thickness of the rectal wall. Two patients incurred a rectal fistula.
During the trial, it was assumed that the rectum was as sensitive as prostate tissue, since there were very limited observations of rectal damage from the phase I trial. Following the current trial, a retrospective analysis was performed. In those patients where non-perfused rectal tissue was observed on MRI, a threshold for rectal damage was calculated based on the light dose received at the border between perfused and non-perfused rectal tissue (as was done for the prostate, see section 3.3). The rectal D T,db was found to be approximately an order of magnitude lower than the prostate D T,db in these patients (the average ratio of prostate D T,db to rectal D T,db = 14.1:1), i.e. the rectal tissue in patients with rectal damage appears to be more sensitive to TOOKAD-VTP than the prostate tissue.
There was little difference, however, in the rectal doses received by patients with and without rectal damage. The rectal D 10 value, which represents the top end of the rectal DVH, was 14.0 ± 12.1 J cm −2 (range: 1.0-32.7) for patients with rectal damage and 13.4 ± 7.8 J cm −2 (range: 1.7-21.8) in patients without rectal involvement. That there is no significant difference between the two groups indicates that the occurrence of rectal damage is due to either a difference in drug delivery to the rectum or to differences in the intrinsic sensitivity of the rectal tissue to TOOKAD-VTP.
In neither of the two patients with rectal fistula was the light dose to the rectum (either predicted by the treatment reconstruction simulation or measured by the rectal dosimetry probe) abnormally high.
Until the factors contributing to the rectal sensitivity to TOOKAD-VTP can be determined, it may be desirable to specify a threshold dose for rectal tissue that is lower than that for prostate. This approach will reduce the chance of rectal complications. Small amounts of damage rectal tissue seem, however, to be well tolerated in most patients and return of contrast enhancement on MRI, which is consistent with healing of the rectal wall, was noted six months post-treatment in all but one of the patients with rectal wall involvement.
Discussion
In this study, we have applied techniques commonly used in radiation therapy to the planning and analysis of prostate VTP. The importance of PDT treatment planning has been recognized by many authors but, to our knowledge, the use of dose distribution analysis tools such as the dose-volume histogram has been applied only to a limited extent in clinical photodynamic therapy. Of note, both Altschuler et al (2005) and Johansson et al (2007) use dose-volume histograms to evaluate the ability of optimization routines to improve the dose distribution within a prostate but clinical outcomes were not used in the evaluation.
The light dose received by the tissue is more important to the success of a PDT treatment than the amount of energy delivered by the treatment fibres. Traditionally, PDT for surface lesions requires a fixed light dose at the surface. This prescription, however, is based on the light dose received below the surface. A one-size-fits-all fixed light dose for interstitial PDT will result in delivering a sub-optimal treatment for most patients. The adoption of treatment planning techniques that are well established in radiotherapy should benefit the development of interstitial PDT by providing some degree of assurance that sufficient light doses are being delivered to the target tissue(s).
The American Association of Physicists in Medicine (Rivard et al 2004) recommends that any clinical implementation of brachytherapy treatment planning achieve a ±2% agreement with a standard set of dose-rate profiles, which is much stricter than our ±44% accuracy in predicting fluence rate values. The recommendation is based, however, on the ability to derive a consensus dataset of the parameters required to calculate the radiation dose rate around a radioactive seed. This is much easier to achieve in radiotherapy since the tissue attenuation is uniform across the patient population while in PDT, there is inter-patient variation in optical properties. The rapid fall-off in light intensity means that our error in predicting an iso-fluence contour location is approximately ±2 mm for an average set of optical properties. By reducing the fluence rate prediction error to ±10%, we can reduce the iso-fluence contour position error to approximately ±0.5 mm. Further analysis of clinical trials with well-controlled treatment delivery and dosimetry is required to establish firm guidelines for PDT treatment planning accuracy.
Validation of other PDT treatment planning technology using in vivo data is limited. Of note, Jankun et al (2005) were able to predict PDT lesion radii to within ±2 mm in normal canine prostate. We have shown a similar accuracy in predicting the location of a light dose contour.
The accuracy of the calculated dose values is directly related to the accuracy of the reconstructed light intensity value. Hence, the dose values (D T,db , D T,50% , D 90 ) presented above have an accuracy of approximately ±44%. One of the main limitations in achieving greater accuracy is that the treatment reconstructions require transfer of information between ultrasound and MRI images. The shape of the prostate appears different between the two modalities because of the presence of the trans-rectal probe in the ultrasound images and because of differences in patient position between the two image series. This creates difficulties when mapping planned fibre locations into the intra-operative imaging space and mapping actual fibre locations into the treatment reconstructions. Planning on baseline ultrasound images would provide a closer match between the treatment plan and the intraoperative imaging but measurement of the treatment effect on MRI still requires transfer of information between modalities. We are currently investigating the integration of deformable registration (Hensel et al 2007) into the planning and reconstruction processes to deal with this issue.
Three different methods for determining the threshold light dose have been presented. Two (D T,db and D T,50% ) compare the light dose with tissue damage measured on post-treatment MRI. The third, D 90 , compares the light dose with biopsy results. The investigation of multiple methods of analysis reflects the evolution of our understanding of the best ways to evaluate threshold doses based on multiple endpoints.
The main advantage of using an analysis based on MRI-observable damage is the short turn-around time. Determination of a MRI-based threshold could be done a week after a patient was treated and, therefore, the knowledge gained from patients treated earlier in the trial informed the treatment strategy for later patients. The usefulness of these thresholds depends, however, on the ability of MRI-based prostate damage measurements to predict the primary treatment outcome, i.e. the negative biopsy rate. All patients with damage volumes greater than 60% of the prostate volume (n = 5) had a complete biopsy response but the remaining three complete responders had damage to less than 30% of the prostate. MRI response was at best a modest predictor for the treatment outcome but it was better than other intermediate endpoints such as change in PSA (Haider et al 2007a) .
The large range in MRI-based threshold dose values poses a challenge in selecting threshold values for future patients. Using median or average values would result in the over-or under-dosing of most patients. This heterogeneity in threshold values is a result of the heterogeneous treatment response but the reasons for the inter-and intra-patient variability in treatment response have yet to be established. Other studies have also noted variability in the treatment response (Moore et al 2006 , Du et al 2006 . There is no evidence that the heterogeneity in our patients is related to the light delivery since there are patients in whom high light doses were measured yet did not incur large damage volumes. Since the success of a PDT procedure also relies on sufficient quantities of photosensitizer and oxygen, the range in observed tissue response may be caused by insufficient amounts of TOOKAD and/or O 2 in the prostate during the laser illumination. Radiotherapy has been shown to affect the vascularity of the prostate (Sheaff and Baithun 1997 ) and blood supply is particularly important to TOOKAD treatments since it is a vascular-targeted agent. Differences in blood supply could affect the quantity of TOOKAD reaching the prostate and the timing of the peak intra-prostatic concentration. Low blood supply could also lead to oxygen depletion. Work is currently proceeding to develop interstitial photosensitizer and oxygen dosimetry , Chang et al 2007 that can be combined with light distribution data to generate a threshold PDT Dose.
The use of in vivo measurements of light attenuation, photosensitizer concentration and oxygenation and the ability to adapt to changes in these parameters over the course of the treatment have been highlighted by most groups performing prostate PDT. Because of the relatively short time in which TOOKAD remains in the body, there are limits on which treatment parameters are adjustable (e.g. increasing the irradiation time will have limited usefulness without altering the drug delivery method) but we are working towards a strategy of adjusting the treatment plan based on pre-infusion measurements of light intensity in the prostate, thereby correcting for optical attenuation.
A case can still be built for the importance of treatment planning in these patients despite the variability in treatment response. A treatment plan provides the optimum treatment parameters within the observed variability, which an ad hoc approach cannot provide. Treatment planning also provides a rational approach to re-treatment through analysis of the initial treatment.
Both radiological and histological data from the trial show sharp demarcations between affected and unaffected tissue and, therefore, support the use of the threshold model for TOOKAD-VTP. The heterogeneity in the threshold values is not an indication that the threshold model is invalid but that other factors in addition to light are required to define the threshold dose.
Despite the heterogeneity, the MRI-based threshold analyses have provided insight into the response to TOOKAD-VTP. The D T,db , when based on the 10th percentile of the dose histogram along the non-perfused tissue border, provides an estimate of the minimum light dose required for prostate damage and, therefore, of the maximum potential extent of prostatic damage. The prostate volume receiving a light dose greater than D T,50% , in those patients in whom D T,50% could be defined, correlates well with the prostate damage volume. It follows that complete prostate de-vascularization can be achieved in these patients given a sufficiently large light dose. Whether a patient belongs in this subset cannot be known without multiple treatments at different light doses but the data presented in figure 7 suggest that complete prostate devascularization can be achieved in approximately 50% of the per-protocol population.
A threshold dose (D 90 ) based on the primary endpoint of the treatment, which in this case is six-month biopsy, is preferred over one based on a surrogate marker (MRI-visible damage). The D 90 analysis also presents a narrower range of values from which to choose a threshold dose for future patients, thus avoiding the issue of heterogeneity in the MRI-based threshold dose values. Figure 9 shows a clear delineation between a dose group where there is no complete biopsy response and one where more than 60% of patients had complete response. Achieving minimum light dose conditions based on analysis of D 90 data lends confidence that complete response can be achieved. It should be noted, however, that the response rate may decrease with longer follow-up and that there are cases in which sextant biopsy is not the most reliable biopsy technique (Abdel-khalek et al 2004) .
Our recommendations for minimum D 90 values in TOOKAD-VTP are based on the analysis of the light distribution throughout the entire prostate. Recent developments in the analysis of dynamic MRI have indicated its potential to localize tumours in the peripheral zone of the prostate (Rouviere et al 2004 , Haider et al 2007b . Analysing the dose received by the cancerous tissue might result in a higher response rate. Dynamic MRI performed on all patients in the trial and evaluation of the dose received at the suspected tumour locations is currently ongoing. This analysis may lead to the prescription of an additional dose boost to the suspected tumour location. Minimum dose values for the entire prostate gland might still be maintained since prostate cancer is generally multi-focal and distributed throughout the gland but the approach to planning presented here would still be applicable in a focal therapy that targeted the index lesion.
Conclusions
Treatment planning based on the predicted light dose distribution in the prostate and surrounding tissues has been applied to a phase II trial of TOOKAD-mediated VTP for prostate cancer. It has been shown that a numerical solution to the diffusion equation can predict the location of an iso-fluence contour in interstitial PDT with an accuracy of approximately ±2 mm. Using the same planning technology to reconstruct treatments delivered in the trial, it was demonstrated that there is a large inter-and intra-patient heterogeneity in the threshold light dose for TOOKAD-VTP-induced damage in irradiated prostate tissue. The heterogeneity was not, however, related to the accuracy of the light dose predictions. The reason for this heterogeneity, whether it is related to photosensitizer concentration, oxygen supply or intrinsic sensitivity to the treatment, has yet to be determined. It was shown in some patients that the proportion of tissue that becomes de-vascularized rises with the light dose received by the tissue while in other patients tissue receiving a high light dose does not necessarily become damaged. By analysing the light dose-volume histograms generated from the reconstruction simulations, it was determined that no patient with a minimum light dose received by 90% of the prostate (D 90 ) less than 23 J cm −2 had complete biopsy response at six months posttreatment while all biopsies were negative in 8 of 13 patients with D 90 > 23 J cm −2 . In patients with VTP-induced rectal damage, the threshold light dose for rectal de-vascularization was much lower than that for prostate tissue. Rectal damage was observed in patients with a maximum rectal dose as low as 10 J cm −2 .
